23 Nov

First commercial scans with I-MED to commence in December

ASX announcement ASX:4DX The future of lung health Melbourne 5/468 St. Kilda Rd, Melbourne, Victoria, 3004 Los Angeles 21600 Oxnard St #300, Woodland Hills, 91367, CA 4DMedical L imi t e d ABN: 31 161 684 831 Email: info@4DMedical.com 1 Tel: +61 (3) 9545 5940 Tel: +1 (818) 794 - 6467 www.4 DM edical.com First commercial scans with I - MED to commence in December 2 3 November 2021 Highlights • Commercial rollout of XV L V AS ™ software with I - MED, Australia’s largest diagnostic imaging provider, commencing with an initial clinic in December 2021 , with two more to follow in early 2022 • Commercial arrangement follows completion of 4DMedical’s detailed 12 - month pilot program with I - MED and follows overwhelming ly positive feedback from radiologists and patients • First revenues from I - MED will be received with commencement of commercial rollout • Broader commercial expansion across the I - MED network is subject to successful rollout of the initial clinics • I - MED has nationwide coverage representing significant opportunity for XV L V AS ™ in Australia alone • 4DMedical has a strong near - term commercialisation pipeline in the large, valuable US market , in particular within the V eterans A ffair s healthcare system • Strong cash position with $ 72.2 million held as at 30 September 2021 and well - funded to scale - up and execute commercialisation opportunities 4DMedical Limited (ASX:4DX, “ 4DMedical ” , or the “ Company ” ), a medical technology company focus ed on commercialising its FDA - cleared and TGA - approved respiratory imaging platform, is pleased to announce the commercial rollout of its XV Lung Ventilation Analysis Software (XV LVAS™) with I - MED Radiology Network (I - MED) commencing a t the Berwick clinic , Melbourne in December 2021. The commencement of the commercial arrangement follows the successful completion of piloting programs by 4DMedical in collaboration with I - MED. I - MED is Australia’s largest diagnostic imaging provider with more than 2 5 0 clini cs nationwide. “Beginning December, patients can be referred to the I - MED Radiology Network clinic serving Casey,” said 4DMedical’s Managing Director and Chief Executive Officer, Dr Andreas Fouras. “People living with or concerned about respiratory disease will have access to the world’s most advanced four - dimensional quantification and visualisation of their lungs, enabling them and their referring doctor to gain insights into lung function with the highest sensitivity.” “This expansion of our capability at our Berwick clinic means people in Casey and south - eastern Melbourne can access the latest technology in respiratory imaging from December,” added I - MED’s General Manager Government Relations and External Partnerships, Mark Simpson. “ This service enables superior information to be provided to patients presenting with lung disorders and will help referring medical practitioners plan appropriate treatment plans.” Commencement of commercial arrangement with I - MED Commencing in December, clinicians and specialists based in and around the Casey region of Victoria, Australia, will be able to refer patients to I - MED’s imaging clinic in Berwick, where state - of - ©4DMedical Limited 2 www.4DMedical.com the - art radiology infrastructure compatible with 4DMedical’s unique XV Technology has been proven in commercial pilot evaluation studies. Commercial pricing is in line with the Company’s expectations. 4DMedical’s XV LVAS s oftware rollout will be rapidly expanded to include sites in Brisbane and Wagga Wagga in early 2022 , and at selected locations across I - MED’s network thereafter . Valuable insights and important learnings gained during p ilot studies in Casey and Launceston have usefully informed clinical interventions following interpretation of 4DMedical’s Ventilation Reports by specialist thoracic radiologists and general practitioners. Disease indication analysis during piloting span ned conditions including post - COVID, asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, sarcoidosis , and silicosis. 4DMedical’s XV Technology is particularly useful as a surveillance tool, monitoring the evolving condition of patients’ lungs and response to therapeutic interventions , such as courses of pharmaceuticals. Commercial pilot progress & updates In addition to the commercial rollout with I - MED, 4DMedical continues to make progress with commercial pilot s in the United States. Th e Company currently has a strong near - term commercialisation pipeline in the large, valuable US market , in particular within the large and important Veterans Health Administration (VHA) healthcare system . The Company continues to progress towards signing its first commercial agreement in the U . S . – ENDS – Authorised by the 4DMedical Board of Directors. Contacts Corporate Charlene Stahr Company Secretary companysecretary@4dmedical .com Investor Simon Hinsley + 61 401 809 653 shinsley@4dmedical.com Media Matthew Wright + 61 451 896 420 matt@nwrcommunications.com.au About 4DMedical Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX). 4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software - as - a - Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods. Respiratory diagnos tics is a US$31 billion per annum global industry. Through its technology , 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from 4DMedical Limited (ASX:4DX) when you join Listcorp.